RBC Capital Maintains Outperform on Biogen, Raises Price Target to $341
Portfolio Pulse from richadhand@benzinga.com
RBC Capital analyst Brian Abrahams has maintained an 'Outperform' rating on Biogen (NASDAQ:BIIB) and raised the price target from $332 to $341.
July 11, 2023 | 12:22 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital has maintained an 'Outperform' rating on Biogen and raised the price target from $332 to $341, which could positively impact the stock.
The 'Outperform' rating indicates that the analyst expects Biogen to do better than the market average. The increase in price target from $332 to $341 suggests that the analyst sees potential for the stock's price to rise. This could lead to increased investor confidence and a potential increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100